Attenuation of haloperidol induced orofacial dyskinesia by ginkgo biloba extract
International Journal of Applied Behavioral Sciences,
Vol. 2 No. 3 (2015),
20 January 2016
,
Page 22-28
https://doi.org/10.22037/ijabs.v2i3.11198
Abstract
Introduction: Tardive dyskinesia is one of the major side effects of long-term neuroleptic treatment. Increased reactive oxygen species and oxidative stress has been proposed as possible etiopathologic mechanisms. Ginkgo biloba extract (EGB) is a natural antioxidant. We investigated the effects of ginkgo biloba extract on neuroleptic-induced orofacial dyskinesia in rats, a potential animal model for tardive dyskinesia.Methods: Orofacial dyskinesia was induced by chronic administration of haloperidol (1 mg/kg i.p) for a period of 21 days. On 22nd day, animals were assessed for development of oral dyskinesia. Malon di aldehyde (MDA), glutathione (GSH), superoxide dismutase (SOD) and catalase levels were evaluated in animal forebrain homogenate.Results: Chronic haloperidol (1 mg/kg) treatment significantly increased the vacuous chewing movement’s frequency, increased MDA and decreased SOD and catalase levels. Co-administration of EGB 25 mg/kg along with haloperidol suppressed the haloperidol induced vacuous chewing movements (Pvalue < 0.05). EGB 100 mg/kg reversed haloperidol induced reduction in SOD level. It also reversed the increment in MDA level observed in haloperidol treated rats.Conclusion: The present study suggested that oxidative stress plays a significant role in neuroleptic-induced orofacial dyskinesia and EGB co-administration reverses these behavioral and biochemical changes.Declaration Interest: None.
- Movement Disorders
- Neuroleptics
- Gingo Biloba
- Dyskinesia
- Psychomotor Disorders
How to Cite
References
Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23(4):583-609.
Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61 Suppl 4:5-9.
Kulkarni SK, Naidu PS. Tardive dyskinesia: An update.Drugs Today (Barc). 2001;37(2):97-119.
Aquino CCH, Lang AE. Tardive dyskinesia syndromes:current concepts. Parkinsonism & related disorders. 2014;20:S113-S7.
Brondino N, De Silvestri A, Re S, Lanati N, Thiemann P, Verna A, et al. A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine. EvidenceBased Complementary and Alternative Medicine.
;2013.
Cadet JL, Lohr, J.B., Jeste, D.V. Free radicals and tardive
dyskinesia. Trends Neurosci. 1986(9):107–8.
Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262(5134):689-95.
Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol. 2000;61(5):525-41.
Balijepalli S, Kenchappa RS, Boyd MR, Ravindranath V. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem Int. 2001;38(5):425-35.
Naidu PS, Kulkarni SK. Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy. Methods Find Exp Clin Pharmacol. 2004;26(5):323-6.
Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull. 1999;25(4):731-40.
Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-76.
Richardson MA, Haugland G, Pass R, Craig TJ. The prevalence of tardive dyskinesia in a mentally retarded population.Psychopharmacol Bull. 1986;22(1):243-9.
Gupta S, Mosnik D, Black DW, Berry S, Masand PS. Tardive dyskinesia: review of treatments past, present, and future. Ann Clin Psychiatry. 1999;11(4):257-66.
Soares KV, McGrath JJ. Vitamin E for neurolepticinduced Rev. 2000(2):CD000209.
Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug design, development and therapy. 2013; 7:1329.
Pehlivan M, Dalbeler Y, Hazinedaroglu S, Arikan Y, Erkek AB, Gunal O, et al. An assessment of the effect of Ginkgo Biloba EGb 761 on ischemia reperfusion injury of intestine. Hepatogastroenterology.
;49(43):201-4.
Maitra I, Marcocci L, Droy-Lefaix MT, Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochem Pharmacol. 1995; 49(11):1649-55.
Kusmic C, Basta G, Lazzerini G, Vesentini N, Barsacchi R. The effect of Ginkgo biloba in isolated ischemic/reperfused rat heart: a link between vitamin E preservation and prostaglandin biosynthesis. J
Cardiovasc Pharmacol. 2004;44(3):356-62.
Zeybek N, Gorgulu S, Yagci G, Serdar M, Simsek A, Kaymakcioglu N, et al. The effects of gingko biloba extract (EGb 761) on experimental acute pancreatitis. J Surg Res. 2003;115(2):286-93.
Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, et al. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, Attenuation of haloperidol induced orofacial dyskinesia.
Naidu PS, Kulkarni SK. Effect of 5-HT1A and 5- HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol. 2001;428(1):81-6.
Naidu PS, Singh A, Kulkarni SK. Carvedilol attenuates
neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol. 2002; 136(2): 193-200.
Ahmad M SS, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal AK, Islam F. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and
immunohistochemical evidences. J Neurochem. 2005.
Shivakumar BR, Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther. 1993;265(3):1137-41.
Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192 (4238): 481-3.
See RE. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride.Neurosci Lett. 1991;129(2):265-8.
Spina MB, Cohen G. Hydrogen peroxide production in dopamine neurons. Basic Life Sci. 1988;49:1011-4.
Vairetti M, Feletti F, Battaglia A, Pamparana F, Canonico PL, Richelmi P, et al. Haloperidol-induced changes in glutathione and energy metabolism: effect of nicergoline. Eur J Pharmacol. 1999;367(1):67-72.
Ravindranath V, Reed DJ. Glutathione depletion and formation of glutathione-protein mixed disulfide following exposure of brain mitochondria to oxidative stress. Biochem Biophys Res Commun. 1990;169 (3):1075-9.
Nielsen EB, Lyon M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenithixol) in rats. Psychopharmacology (Berl). 1978;59(1):85-9.
Bridi R, Crossetti FP, Steffen VM, Henriques AT. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res. 2001; 15(5): 449-51.
Chao JC, Hung HC, Chen SH, Fang CL. Effects of Ginkgo biloba extract on cytoprotective factors in rats with duodenal ulcer. World J Gastroenterol. 2004;10(4):560-6.
Yao P, Li K, Song F, Zhou S, Sun X, Zhang X, et al. Heme oxygenase-1 upregulated by Ginkgo biloba extract: potential protection against ethanol-induced oxidative liver damage. Food Chem Toxicol. 2007;45(8):1333-42.
Naidu PS, Singh A, Kulkarni SK. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology. 2003;44(8):1100-6.
Zhang XY, Zhang W-F, Zhou D-F, Xiu MH, Wu H-R, Haile CN, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biological psychiatry. 2012;72(8):700-6.
Zhang W-F, Tan Y-L, Zhang X-Y, Chan R, Wu H-R, Zhou D-F. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry. 2011;72(5):615-21.
Kehr J, Yoshitake S, Ijiri S, Koch E, Nöldner M, Yoshitake T. Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®. International
Psychogeriatrics. 2012;24(S1):S25-S34.
- Abstract Viewed: 349 times
- PDF Downloaded: 175 times